Skip to main content
STOK
NASDAQ Life Sciences

Stoke Therapeutics Reports Strong 2025 Financials with Reduced Net Loss and Pipeline Advancement

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$33.11
Mkt Cap
$1.94B
52W Low
$5.35
52W High
$40.22
52W Position info
519% above low
Off High info
18% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

STOK has more than doubled off its 52-week low of $5.35.

Summary

Stoke Therapeutics reported a significant reduction in net loss and a substantial increase in revenue for 2025, extending its cash runway into 2028, alongside continued clinical progress for its lead drug candidates.


Key Events · Earnings and Guidance · STOK

  • Significant Financial Improvement in 2025

    The company reported a net loss of $6.9 million for the year ended December 31, 2025, a substantial improvement from a net loss of $89.0 million in 2024. Revenue surged to $184.4 million in 2025 from $36.6 million in 2024, primarily driven by the Biogen collaboration.

  • Extended Cash Runway into 2028

    Stoke Therapeutics ended 2025 with $390.9 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into 2028.

  • Advancement of Lead Clinical Programs

    The global Phase 3 EMPEROR study for zorevunersen (STK-001) in Dravet syndrome initiated in May 2025, with enrollment expected to complete in Q2 2026 and pivotal data anticipated in mid-2027. The Phase 1 OSPREY study for STK-002 in Autosomal Dominant Optic Atrophy (ADOA) dosed its first patient in February 2026.

  • Acadia Collaboration Program Terminations

    Acadia Pharmaceuticals Inc. terminated the MECP2 and an undisclosed neurodevelopmental program effective September 3, 2025, resulting in Stoke Therapeutics losing eligibility for up to $662.5 million in potential milestones from these programs. The SYNGAP1 collaboration with Acadia remains ongoing.


Analysis · STOK · Life Sciences

Stoke Therapeutics' 2025 annual report highlights a significant financial turnaround, driven by a substantial increase in revenue and a dramatic reduction in net loss. The company's cash position provides a solid runway into 2028, supporting ongoing clinical development for its lead programs. While the termination of certain Acadia collaboration programs is a setback, the progress in the Phase 3 EMPEROR study for Dravet syndrome and the initiation of the Phase 1 OSPREY study for ADOA demonstrate continued pipeline advancement. The adoption of multiple Rule 10b5-1 plans by insiders is a notable, albeit pre-planned, selling signal.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, STOK was trading at $33.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $5.35 to $40.22. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

STOK - Latest Insights

STOK
Nov 03, 2026, 4:05 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $26.99
Real-time Price: $26.94 info
Change: -$0.050 (-0.19%) info
Market Cap: $1.761B info
STOK
Oct 29, 2026, 4:01 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $26.36
Real-time Price: $26.94 info
Change: +$0.580 (+2%) info
Market Cap: $1.761B info
STOK
Oct 21, 2026, 4:42 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $25.68
Real-time Price: $26.94 info
Change: +$1.26 (+5%) info
Market Cap: $1.761B info
STOK
Oct 05, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $25.62
Real-time Price: $26.94 info
Change: +$1.32 (+5%) info
Market Cap: $1.761B info
STOK
Sep 03, 2026, 7:30 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $29.99
Real-time Price: $26.94 info
Change: -$3.05 (-10%) info
Market Cap: $1.761B info